aTYR PHARMA (ATYR) Return on Capital Employed (2015 - 2026)
aTYR PHARMA's (ATYR) quarterly Return on Capital Employed came in at 98.21% in Q1 2026, down 2056.0% YoY from 5.02% in Q1 2025, and down 7.13% on a QoQ basis from 91.67% in Q4 2025.
aTYR PHARMA (ATYR) Return on Capital Employed (2015 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 12 years of Return on Capital Employed data on file, last reported at 98.21% in Q1 2026.
- Quarterly Return on Capital Employed fell 2056.0% year-over-year to 98.21% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 98.21% (down 2056.0% YoY) and the FY2025 annual result came in at 97.32%, down 2489.0% from the prior year.
- Return on Capital Employed declined to 98.21% in Q1 2026, from 91.67% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 37.72% in Q1 2022 to a low of 98.21% in Q1 2026.
- A 5-year average of 64.71% and a median of 58.2% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed soared 2107 bps — and 2024, when it slumped 3995 bps.
- Tracing ATYR's Return on Capital Employed over 5 years: stood at 56.55% in 2022, then grew by 9 bps to 51.59% in 2023, then plunged by 66 bps to 85.69% in 2024, then dropped by 7 bps to 91.67% in 2025, then declined by 7 bps to 98.21% in 2026.
- The last three Return on Capital Employed figures came in at 98.21% (Q1 2026), 91.67% (Q4 2025), and 88.96% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | -100.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -100.81% |
| Mar 31, 2026 | -98.21% |
| Dec 31, 2025 | -91.67% |
| Sep 30, 2025 | -88.96% |
| Jun 30, 2025 | -83.53% |
| Mar 31, 2025 | -77.65% |
| Dec 31, 2024 | -85.69% |
| Sep 30, 2024 | -80.38% |
| Jun 30, 2024 | -63.96% |
| Mar 31, 2024 | -58.20% |
| Dec 31, 2023 | -51.59% |
| Sep 30, 2023 | -40.43% |
| Jun 30, 2023 | -39.03% |
| Mar 31, 2023 | -45.60% |
| Dec 31, 2022 | -56.55% |
| Sep 30, 2022 | -55.52% |
| Jun 30, 2022 | -45.35% |
| Mar 31, 2022 | -37.72% |
| Dec 31, 2021 | -29.91% |
| Sep 30, 2021 | -37.60% |